{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:12Z","timestamp":1792643892766,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.urology.2026.10.005","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:57:18Z","timestamp":1791561438000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9930-6493","authenticated-orcid":false,"given":"Jacob E.","family":"Tallman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Hyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush K.","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah F.","family":"Faris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth K.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.10.005_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib2","first-page":"690","volume":"78","author":"Grimm","year":"2020"},{"key":"10.1016\/j.urology.2026.10.005_bib3","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1111\/ans.70281","article-title":"BCG intolerance in nonmuscle invasive bladder cancer\u2014a systematic review","volume":"95","author":"Oh","year":"2025","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.urology.2026.10.005_bib4","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.21037\/tau-2025-483","article-title":"Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence","volume":"14","author":"Albakr","year":"2025","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib6","unstructured":"National Comprehensive Cancer Network: Bladder Cancer. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf, accessed April 13, 2026."},{"key":"10.1016\/j.urology.2026.10.005_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1464-410X.2008.07740.x","article-title":"Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis","volume":"102","author":"Chuang","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2026.10.005_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 .countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.urology.2026.10.005_bib9","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.urology.2026.10.005_bib10","unstructured":"Federal Reserve Bank of St. Louis: Personal consumption expenditures: Health (chain-type price index). 2026. Available at: https:\/\/fred.stlouisfed.org\/series\/DHLTRG3A086NBEA."},{"key":"10.1016\/j.urology.2026.10.005_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1475-6773.12612","article-title":"Adjusting health expenditures for inflation: a review of measures for health services research in the United States","volume":"53","author":"Dunn","year":"2018","journal-title":"Health Serv Res"},{"key":"10.1016\/j.urology.2026.10.005_bib12","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000005037","article-title":"Management of intravesical therapy-related lower urinary tract symptoms-leveraging existing options to improve outcomes","author":"Tallman","year":"2026","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/JU.0000000000004658","article-title":"Use of rectal diazepam to prevent bladder spasms and leakage of medication during intravesical administration of nadofaragene firadenovec for Bacillus Calmette-Gu\u00e9rin\u2013unresponsive nonmuscle-invasive bladder cancer","volume":"214","author":"Moyer","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU Guideline on the diagnosis and treatment of idiopathic overactive bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urology.2020.04.109","article-title":"Racial and socioeconomic factors influence utilization of advanced therapies in commercially insured OAB patients: an analysis of over 800,000 OAB patients","volume":"142","author":"Syan","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2026.10.005_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.urology.2022.11.006","article-title":"National trends in third-line treatment for overactive bladder among commercially insured women, 2010-2019","volume":"175","author":"Edge","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2026.10.005_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/UPJ.0000000000000496","article-title":"Who progresses to third-line therapies for overactive bladder? Trends from the AQUA Registry","volume":"11","author":"Jericevic","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2026.10.005_bib18","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JU.0000000000001950","article-title":"Patient perceptions impact progression to third-line therapy for treatment of overactive bladder","volume":"206","author":"Iyer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib19","first-page":"343","article-title":"Ideal candidates for bladder preservation in muscle-invasive bladder cancer","volume":"44","author":"Oberoi","year":"2026","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urology.2026.10.005_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11934-024-01250-4","article-title":"Management of lower urinary tract symptoms during the treatment for non-muscle invasive bladder cancer","volume":"26","author":"Seiden","year":"2025","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.urology.2026.10.005_bib21","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical Bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2026.10.005_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Gu\u00e9rin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2026.10.005_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.11.007","article-title":"Quinolone prophylaxis in conjunction with Bacillus Calmette-Gu\u00e9rin instillations for bladder cancer: time to reconsider the evidence and open the quinolone box?","volume":"10","author":"Liedberg","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2026.10.005_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4111\/icu.20220179","article-title":"Role of oral pentosan polysulfate in Bacillus Calmette\u2013Gu\u00e9rin therapy in patients with non-muscle-invasive bladder cancer","volume":"63","author":"Lee","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.10.005_bib26","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3390\/jcm13072031","article-title":"Treating BCG-induced cystitis with combined chondroitin and hyaluronic acid instillations in bladder cancer","volume":"13","author":"Pichler","year":"2024","journal-title":"JCM"},{"key":"10.1016\/j.urology.2026.10.005_bib27","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s11255-025-04375-8","article-title":"Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy","volume":"57","author":"Gubbiotti","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urology.2026.10.005_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4081\/aiua.2018.1.11","article-title":"Intravesical administration of combined hyaluronic acid and chondroitin sulfate can improve symptoms in patients with refractory bacillus Calmette-Guerin-induced chemical cystitis: preliminary experience with one-year follow-up","volume":"90","author":"Imperatore","year":"2018","journal-title":"Arch Ital Urol Androl"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526006655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526006655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:46:06Z","timestamp":1792640766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526006655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S0090429526006655"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.10.005","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}